It is conceivable that testing tumors for TM4SF expression, in combination with other molecular and biochemical assays, may improve the prognostic evaluation of gastric cancer patients, and enhance the clinician's ability to prospectively identify patients who will have early disease recurrence and who require adjuvant chemotherapy. Here, TSPAN1 is linked to gastric cancer.